Transforming access to esophageal care
We are a leading gastrointestinal health company delivering minimally invasive diagnostics for everyone, everywhere.
Explore
Impact
Earlier matters
Esophageal cancer is one of the fastest-growing cancers. Barrett's Esophagus is the only known precursor to Esophageal Adenocarcinoma, yet fewer than 10% of patients have a prior diagnosis.
Only
1 in 5
people with esophageal
cancer survive their diagnosis
cancer survive their diagnosis
EndoSign® is a minimally-invasive capsule sponge device that enables safe and accessible cell collection with full esophageal sampling.
Learn more about our advanced molecular diagnostics:
Recent news
View All
16
April 2026
Cyted Health’s US Laboratory Achieves College of American Pathologists Accreditation
Read more
No items found.
05
December 2025
Cytoprime2 Study Proves Effectiveness of EndoSign® Capsule Sponge Test in Community Care for Early Detection of Esophageal Cancer
Read more
No items found.
30
August 2025
Cyted Health Secures $44 Million in Series B Financing to Accelerate US Expansion
Read more
No items found.
Get in touch for more information about our early cancer test and data-driven diagnostics.
Get in touch
